Kyprolis Drug Interactions
Currently displaying 224 drugs known to have a moderate interaction with Kyprolis (carfilzomib).
- 107 major drug interactions
- 224 moderate drug interactions
Moderate interactions with Kyprolis (carfilzomib)
Note: Showing generic names only.
A
- adenovirus vaccine
- ado-trastuzumab emtansine
- alefacept
- alemtuzumab
- amiodarone
- anakinra
- anifrolumab
- anthrax vaccine adsorbed
- asparaginase erwinia chrysanthemi
- asparaginase escherichia coli
- atorvastatin
- auranofin
- aurothioglucose
- azathioprine
B
- bedaquiline
- benznidazole
- bifidobacterium infantis
- black cohosh
- bortezomib
- brentuximab
- brewer's yeast
C
- cabazitaxel
- calaspargase pegol
- canakinumab
- candida albicans extract
- cannabidiol
- carboplatin
- cerivastatin
- chloramphenicol
- chloroquine
- cholera vaccine
- cholera vaccine, live
- cisplatin
- clofarabine
- coccidioidin skin test
- colchicine
- crizotinib
D
- daclizumab
- dapsone
- denosumab
- didanosine
- digoxin
- dimethyl fumarate
- dinutuximab
- diroximel fumarate
- disulfiram
- docetaxel
E
- efalizumab
- efavirenz
- efbemalenograstim alfa
- eflapegrastim
- elotuzumab
- elranatamab
- enfortumab vedotin
- eribulin
- ethambutol
- ethionamide
- etoposide
- etravirine
F
G
H
- haemophilus b conjugate (hboc) vaccine
- haemophilus b conjugate (prp-omp) vaccine
- haemophilus b conjugate (prp-t) vaccine
- hepatitis a adult vaccine
- hepatitis a pediatric vaccine
- hepatitis b adult vaccine
- hepatitis b pediatric vaccine
- histoplasmin
- human papillomavirus vaccine
- hydralazine
- hydroxychloroquine
I
- idelalisib
- influenza virus vaccine, h1n1, inactivated
- influenza virus vaccine, h5n1
- influenza virus vaccine, inactivated
- interferon alfa-2a
- interferon alfa-2b
- interferon alfa-n1
- interferon alfacon-1
- interferon beta-1a
- interferon beta-1b
- iodoquinol
- ipilimumab
- isoniazid
- ixabepilone
- ixazomib
J
L
- lactobacillus acidophilus
- lactobacillus reuteri
- lactobacillus rhamnosus
- lactobacillus rhamnosus gg
- levodopa
- linezolid
- lovastatin
- lyme disease vaccine
M
- meningococcal conjugate vaccine
- meningococcal group acwy conjugate-group b vaccine (cvx 316)
- meningococcal group B vaccine
- meningococcal polysaccharide vaccine
- methotrexate
- metronidazole
- mirvetuximab soravtansine
- mixed respiratory vaccine
- monomethyl fumarate
- mosunetuzumab
- mumps skin test antigen
N
O
P
- paclitaxel
- paclitaxel protein-bound
- palifermin
- pegaspargase
- pegfilgrastim
- peginterferon alfa-2a
- peginterferon alfa-2b
- peginterferon beta-1a
- pertussis, acellular
- pitavastatin
- plague vaccine
- pneumococcal 13-valent vaccine
- pneumococcal 15-valent conjugate vaccine
- pneumococcal 20-valent conjugate vaccine
- pneumococcal 23-polyvalent vaccine
- pneumococcal 7-valent vaccine
- polatuzumab vedotin
- poliovirus vaccine, inactivated
- pomalidomide
- ponatinib
- pravastatin
R
- rabies vaccine, human diploid cell
- rabies vaccine, purified chick embryo cell
- red yeast rice
- remdesivir
- repotrectinib
- rifampin
- rilonacept
- roflumilast
- ropeginterferon alfa-2b
- rosuvastatin
- rsv vaccine pref3, recombinant
- rsv vaccine, pref a-pref b, recombinant
S
- saccharomyces boulardii lyo
- sargramostim
- sars-cov-2 (covid-19) ad26 vaccine, recombinant
- sars-cov-2 (covid-19) chadox1 vaccine, recombinant
- sars-cov-2 (covid-19) mrna (tozinameran 12y+) bivalent booster vaccine
- sars-cov-2 (covid-19) mrna (tozinameran 5y-11y) bivalent booster vaccine
- sars-cov-2 (covid-19) mrna (tozinameran 6m-4y) bivalent booster vaccine
- sars-cov-2 (covid-19) mrna (tozinameran 6m-4y) bivalent vaccine
- sars-cov-2 (covid-19) mrna-1273 (6m-5y bivalent booster) vaccine
- sars-cov-2 (covid-19) mrna-1273 (bivalent booster) vaccine
- sars-cov-2 (covid-19) mrna-1273 bivalent vaccine
- sars-cov-2 (covid-19) mrna-1273 vaccine
- sars-cov-2 (covid-19) mrna-lnp vaccine (cvx 308)
- sars-cov-2 (covid-19) mrna-lnp vaccine (cvx 309)
- sars-cov-2 (covid-19) mrna-lnp vaccine (cvx 310)
- sars-cov-2 (covid-19) mrna-lnp vaccine (cvx 311)
- sars-cov-2 (covid-19) mrna-lnp vaccine (cvx 312)
- sars-cov-2 (covid-19) mrna(tozinameran12y+) bivalent vaccine
- sars-cov-2 (covid-19) nvx-cov2373 vaccine, recombinant
- sars-cov-2 (covid-19) rs-nanoparticle vaccine, recombinant
- sars-cov-2 (covid-19)mrna-1273(6y+ bivalent booster) vaccine
- sars-cov-2 mrna (tozinameran 5y-11y) vaccine
- sars-cov-2 mrna (tozinameran 6m-4y) vaccine
- sars-cov-2 mrna (tozinameran-tris-sucrose) vaccine
- sars-cov-2 mrna (tozinameran) vaccine
- sars-cov-2 mrna-1273 (6m-5y) vaccine
- sars-cov-2 mrna-1273 (6y-11y) vaccine
- sars-cov-2 mrna-1273 (booster only) vaccine
- sars-cov-2 nvx-cov2373 vaccine, recomb (cvx 313)
- sars-cov-2 pres dtm (booster only) vaccine, recombinant
- sars-cov-2(covid-19)mrna(tozinameran 5y-11y)bivalent vaccine
- secnidazole
- selinexor
- simvastatin
- sipuleucel-T
- skin test antigens, multiple
- smallpox and monkeypox vaccine
- sodium phosphate p32
- staphage lysate (spl)
- stavudine
T
- talquetamab
- tbo-filgrastim
- teclistamab
- telbivudine
- teniposide
- tetanus toxoid
- thalidomide
- thioguanine
- tick-borne encephalitis (inactivated) pediatric vaccine
- tick-borne encephalitis (inactivated) vaccine
- tinidazole
- tisotumab vedotin
- tocilizumab
- topotecan
- trabectedin
- trichophyton skin test
- tuberculin purified protein derivative
- typhoid vaccine, inactivated
U
V
- valganciclovir
- valoctocogene roxaparvovec
- vinblastine
- vincristine
- vincristine liposome
- vinorelbine
- vitamin e
Z
Kyprolis alcohol/food interactions
There is 1 alcohol/food interaction with Kyprolis (carfilzomib).
Kyprolis disease interactions
There are 12 disease interactions with Kyprolis (carfilzomib) which include:
- TLS
- cardiac disease
- dyspnea
- hemorrhage
- hepatic toxicity
- hypertension
- PRES
- pulmonary hypertension
- pulmonary toxicity
- renal failure
- TTP/HUS
- venous thrombosis
More about Kyprolis (carfilzomib)
- Kyprolis consumer information
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (3)
- Drug images
- Side effects
- Dosage information
- Patient tips
- During pregnancy
- Generic availability
- FDA approval history
- Drug class: proteasome inhibitors
- Breastfeeding
- En español
Related treatment guides
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.